Integrated safety analysis of anti-programmed cell death-1 (PD-1) antibody penpulimab in advanced solid tumour or lymphoma

被引：0
|
作者：
Xu, N. [1 ]
Han, B. [2 ]
Jiao, S. [3 ]
Hu, C. [4 ]
Mislang, A. [5 ]
Coward, J. [6 ]
Cooper, A. [7 ]
Underhill, C. [8 ]
Xia, Y. [9 ]
Xia, D. [9 ]
Jin, X. [9 ]
Wang, Z. M. [9 ]
Li, B. [9 ]
机构：
[1] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Oncol, Hangzhou, Peoples R China
[2] Shanghai Chest Hosp, Dept Oncol, Shanghai, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China
[4] Shanghai Canc Ctr, Dept Radiotherapy, Shanghai, Peoples R China
[5] Adelaide Canc Ctr, Dept Oncol, Kurralta Pk, Australia
[6] Icon Canc Ctr, Dept Oncol, Brisbane, Qld, Australia
[7] Univ Western Sydney, Sch Med, Dept Oncol, Liverpool, Australia
[8] Albury Wodonga Reg Canc Ctr, Dept Oncol, Albury, NSW, Australia
[9] Akeso Biopharma Inc, Zhongshan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
31P
引用
收藏
页码：S1428 / S1429
页数：2
相关论文
共 50 条
  • [21] A PHASE II STUDY OF THE ANTI-PROGRAMMED CELL DEATH-1 (PD-1) ANTIBODY PENPULIMAB IN PATIENTS WITH METASTATIC NASOPHARYNGEAL CARCINOMA (NPC) WHO HAD PROGRESSED AFTER TWO OR MORE LINES OF CHEMOTHERAPY
    Chen, Xiaozhong
    Wang, Wei
    Zou, Qingfeng
    Li, Jingao
    Hu, Chaosu
    Hu, Chaosu
    Lin, Qin
    Zhu, Xiaodong
    Jiang, Yi
    Sun, Yan
    Shen, Liangfang
    Wang, Lin
    Zou, Guorong
    Lin, Xiaoyan
    Wang, Ying
    Lin, Shaojun
    Li, Minying
    Ao, Rui
    Xu, Ruilian
    Lin, Haifeng
    Wang, Rensheng
    Yang, Jiacheng
    Song, Weifeng
    Wang, Max
    Li, Baiyong
    Xia, Yu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A481 - A481
  • [22] A phase I/II study of the anti-programmed cell death-1 (PD-1) antibody AK105 in patients with relapsed or refractory classic Hodgkin lymphoma (cHL).
    Song, Yuqin
    Zhu, Jun
    Lin, Ningjing
    Zhang, Chen
    Jin, Xiaoping
    Xu, Shuping
    Li, Baiyong
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
    Hamid, Omid
    Carvajal, Richard D.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (06) : 847 - 861
  • [24] Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.
    Nie, Run-Cong
    Yuan, Shu-Qiang
    Li, Yuanfang
    Chen, Yingbo
    Zhou, Zhiwei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma.
    Goldinger, Simone M.
    Tsai, Katy K.
    Tumeh, Paul
    Hamid, Omid
    Nosrati, Adi
    Loo, Kimberly
    Grimes, Barbara
    Algazi, Alain Patrick
    Levesque, Mitchell P.
    Dummer, Reinhard
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors
    Desai, Jayesh
    Markman, Ben
    Sandhu, Shahneen Kaur
    Gan, Hui Kong
    Friedlander, Michael
    Tran, Ben
    Meniawy, Tarek
    Boolell, Vishal
    Colyer, Duncan
    Norris, Christie
    Ameratunga, Malaka
    Yang, Jason
    Li, Kang
    Wang, Lai
    Luo, Lusong
    Qin, Zhen
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies
    Kao, Justin C.
    Liao, Bing
    Markovic, Svetomir N.
    Klein, Christopher J.
    Naddaf, Elie
    Staff, Nathan P.
    Liewluck, Teerin
    Hammack, Julie E.
    Sandroni, Paola
    Finnes, Heidi
    Mauermann, Michelle L.
    JAMA NEUROLOGY, 2017, 74 (10) : 1216 - 1222
  • [28] Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis
    Matsumoto, Kazuyuki
    Miyake, Yasuhiro
    Matsushita, Hiroshi
    Ohnishi, Atsuyuki
    Ikeda, Fusao
    Shiraha, Hidenori
    Takaki, Akinobu
    Nouso, Kazuhiro
    Yamamoto, Kazuhide
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (01) : 110 - 115
  • [29] Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis
    Miyake, Yasuhiro
    Matsumoto, Kazuyuki
    Matsushita, Hiroshi
    Ohnishi, Atsuyuki
    Nakarai, Asuka
    Koike, Kazuko
    Takaki, Akinobu
    Yamamoto, Kazuhide
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 155 - 155
  • [30] Serum Anti-programmed Cell Death-1 Antibody as a Novel Biomarker for Type 1 Autoimmune Hepatitis
    Miyake, Yasuhiro
    Matsumoto, Kazuyuki
    Koike, Kazuko
    Takaki, Akinobu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S872 - S873
12345